Biocodex is a family-owned French multinational pharmaceutical company founded in 1953, focused on microbiota care, women's health, and orphan diseases. Since 2016 it has invested in biotech startups developing innovative therapeutics, becoming a key player in the French biotech ecosystem.
67% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (50% of deals).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
Portfolio
12 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Exeliom Biosciences | Series A | — | Jul 2023 |
| NNextbiotix | Series A | — | Jul 2023 |
| EExeliom Biosciences | Series A | — | Jul 2023 |
 Maat Pharma | Series B | — | Dec 2020 |
 Maat Pharma | Series B | — | Dec 2020 |
| Maat Pharma | Series B | — | Feb 2020 |
| Maat Pharma | Series B | — | Feb 2020 |
| Maat Pharma | Series B | — | Jan 2020 |
| NNextbiotix | Series A | — | Jul 2018 |
| Maat Pharma | Series A | $11M | Jan 2016 |
| Maat Pharma | Series A | $11M | Jan 2016 |
| EExeliom Biosciences | Seed | — | — |
Top Co-Investors
Seventure Partners7 shared
Bpifrance6 shared
SymBiosis5 shared
Capital Grand Est3 shared
UI Investissement3 shared
CE Ventures3 shared
French Tech Seed Fund2 shared
Crescent Capital Group2 shared
Raga Partners1 shared
Crescent Enterprises1 shared
Headline1 shared
Last updated: 20 October 2026